Urine Omics Predicting IO Therapy Responses in mRCC Patients

NCT04712305 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2022-01-20

No results posted yet for this study

Summary

The study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving IO-based therapies for metastatic renal cell carcinoma.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

OTHER

No intervention required

No intervention required

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-04
Primary Completion
2025-12-31
Completion
2027-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04712305 on ClinicalTrials.gov